August 21, 2007

Interim Phase II Results

Intercell AG (ICLL) announced the analysis of Phase II interim data for its peptide-based therapeutic Hepatitis C vaccine (IC41). First data from 25 patients reveals statistically significant viral load reduction and very good safety profile.
Press Release